Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis | ||
| dc.conicet.organizacion | Federacion Argentina de Cardiologia | |
| dc.conicet.organizacion | Sociedad Argentina de Lípidos | |
| dc.conicet.organizacion | Hospital Italiano | |
| dc.conicet.organizacion | Federacion Argentina de Cardiologia | |
| dc.conicet.organizacion | Hospital Italiano | |
| dc.conicet.organizacion | Sociedad Argentina de Lípidos | |
| dc.conicet.organizacion | Federacion Argentina de Cardiologia | |
| dc.conicet.organizacion | Federacion Argentina de Cardiologia | |
| dc.conicet.organizacion | Federacion Argentina de Cardiologia | |
| dc.conicet.organizacion | Sociedad Argentina de Lípidos | |
| dc.conicet.organizacion | Universidad Nacional de Formosa | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste | |
| dc.contributor.author | Masson, Walter | |
| dc.contributor.author | Lobo, Martín | |
| dc.contributor.author | Siniawski, Daniel | |
| dc.contributor.author | Molinero, Graciela | |
| dc.contributor.author | Huerín, Melina | |
| dc.contributor.author | Nogueira, Juan Patricio | |
| dc.date.issued | 2019-08 | |
| dc.description.abstract | Introduction: Previous report showed that more intensive lipid-lowering therapy was associated with less mortality when baseline LDL-C levels were > 100 mg/dL. Non-HDL-C is a better predictor of cardiovascular risk than simpler LDL-C. Aim: The objective of this meta-analysis was to define the impact of lipid-lowering therapy on the reduction of total and cardiovascular mortality by different baseline levels of non-HDL-C. Methods: We performed a meta-analysis including randomized, controlled clinical trials of lipid-lowering therapy, reporting mortality with a minimum of 6 months of follow-up, searching in PubMed/Medline, EMBASE and Cochrane Clinical Trials databases. The random-effects model and meta-regression were performed. Results: Twenty nine trials of lipid-lowering drugs, including 233,027 patients, were considered eligible for the analyses. According to the baseline non-HDL-C level, the results on cardiovascular mortality were: (1) ≥ 190 mg/dL: OR 0.63 (95% CI 0.53–0.76); (2) 160–189 mg/dL: OR 0.82 (95% CI 0.75–0.89); (3) 130–159 mg/dL: OR 0.71 (95% CI 0.52–0.98); (4) < 130 mg/dL: OR 0.95 (95% CI 0.87–1.05). When evaluating mortality from any cause, the results were the following: (1) ≥ 190 mg/dL: OR 0.70 (95% CI 0.61–0.82); (2) 160–189 mg/dL: OR 0.91 (95% CI 0.83–0.98); (3) 130–159 mg/dL; OR 0.88 (95% CI 0.77–1.00); (4) < 130 mg/dL: OR 0.98 (95% CI 0.91–1.06). The meta-regression analysis showed a significant association between baseline non-HDL-C and mortality. Conclusions In these meta-analyses, lipid-lowering therapy was associated with reduction in the risk of all-cause and cardiovascular mortality when baseline non-HDL-C levels were above than 130 mg/dL. | es |
| dc.description.fil | Fil: Masson, Walter. Federacion Argentina de Cardiologia; Argentina. Sociedad Argentina de Lípidos; Argentina. Hospital Italiano; Argentina | |
| dc.description.fil | Fil: Lobo, Martín. Federacion Argentina de Cardiologia; Argentina | |
| dc.description.fil | Fil: Siniawski, Daniel. Hospital Italiano; Argentina. Sociedad Argentina de Lípidos; Argentina. Federacion Argentina de Cardiologia; Argentina | |
| dc.description.fil | Fil: Molinero, Graciela. Federacion Argentina de Cardiologia; Argentina | |
| dc.description.fil | Fil: Huerín, Melina. Federacion Argentina de Cardiologia; Argentina | |
| dc.description.fil | Fil: Nogueira, Juan Patricio. Sociedad Argentina de Lípidos; Argentina. Universidad Nacional de Formosa; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; Argentina | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Masson, Walter; Lobo, Martín; Siniawski, Daniel; Molinero, Graciela; Huerín, Melina; et al.; Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis; Springer; High Blood Pressure and Cardiovascular Prevention; 26; 4; 8-2019; 263-272 | es |
| dc.identifier.eissn | 1179-1985 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 1120-9879 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/150977 | |
| dc.journal.ciudad | Viena | es |
| dc.journal.number | 4 | es |
| dc.journal.pagination | 263-272 | es |
| dc.journal.pais | Suiza | es |
| dc.journal.title | High Blood Pressure and Cardiovascular Prevention | es |
| dc.journal.volume | 26 | es |
| dc.language.iso | eng | es |
| dc.publisher | Springer | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s40292-019-00330-8 | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | LIPID-LOWERING THERAPY | es |
| dc.subject | META-ANALYSIS | es |
| dc.subject | MORTALITY | es |
| dc.subject | NON-HDL-CHOLESTEROL | es |
| dc.subject.classification | Endocrinología y Metabolismo | es |
| dc.subject.classification | Medicina Clínica | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.fc815815-0b4f-44f3-a34d-5a0bf1a9c6ee_A.pdf
- Tamaño:
- 2.77 MB
- Formato:
- Adobe Portable Document Format